Buy Calutide (Bicalutamide) Online — Cipla Selective Non-Steroidal Antiandrogen for Stage D2 Metastatic Prostate Cancer Combined Androgen Blockade

The main reasons Calutide gets prescribed

1. Combined androgen blockade. Given alongside an LHRH agonist injection (leuprolide, goserelin, triptorelin) in advanced or metastatic prostate cancer. The LHRH agonist drops testosterone; Calutide blocks whatever remaining androgen signal exists.

2. To prevent tumour flare. LHRH agonists briefly raise testosterone before they suppress it. Calutide is often started a week before the first LHRH injection to protect against this flare in men with symptomatic bone metastases.

3. Monotherapy at 150 mg in locally advanced disease, when a man wants to preserve libido and sexual function better than castration would allow.

The three main clinical contexts

Advanced or metastatic disease with LHRH agonist: Standard combined androgen blockade. Calutide 50 mg daily plus monthly or three-monthly LHRH injection. Duration usually indefinite until disease progresses.

LHRH agonist tumour flare prevention: Calutide 50 mg daily started 3-7 days before the first LHRH injection and continued for 2-4 weeks after. Prevents the transient testosterone rise from worsening bone pain or spinal cord compression.

Locally advanced monotherapy at 150 mg: Alternative to castration when the man wants to preserve testosterone-driven benefits (libido, energy, muscle mass, mood) at the cost of accepting higher gynecomastia rates. Not licensed everywhere for this indication.

The trade-off in one line

Calutide as monotherapy at 150 mg preserves more masculine function than castration but does not extend life as much in aggressive disease. In combination with an LHRH agonist at 50 mg it adds a modest survival benefit at the cost of side effect stacking. The right choice depends on cancer stage, PSA trajectory, and personal priorities.

Who gets what

• Newly diagnosed metastatic prostate cancer, hormone-sensitive: LHRH agonist + Calutide often started together, though some newer regimens use enzalutamide/apalutamide/darolutamide instead of bicalutamide - see Section 31
• Locally advanced disease, PSA-only recurrence: Calutide monotherapy at 150 mg is one option; LHRH monotherapy or watchful waiting are others
• Symptomatic bone metastases before LHRH start: Calutide flare cover for the first weeks
• Older men with prostate cancer and heart disease: Calutide-based regimens sometimes chosen over full castration to reduce cardiovascular side effect load
• Men who cannot tolerate LHRH agonists due to injection reactions or specific comorbidities

The two arms of blockade

1. LHRH agonist (leuprolide, goserelin, triptorelin): switches off the pituitary signal that tells the testes to make testosterone. Serum testosterone drops to castrate levels (under 50 ng/dL or 1.7 nmol/L) within 3-4 weeks.

2. Calutide 50 mg daily: blocks the androgen receptor so any remaining androgen (adrenal androgens, or intracellular DHT) cannot signal.

Together, this is more complete blockade than either drug alone. Whether the extra 5-10 percent of blockade translates into meaningful survival benefit has been debated for 25 years.

What the meta-analyses show

The Prostate Cancer Trialists' Collaborative Group meta-analysis (Lancet 2000) pooled data from over 8 000 men in 27 trials. Combined androgen blockade with a non-steroidal antiandrogen (like bicalutamide) added about 2-3 percent absolute survival benefit at 5 years versus LHRH alone. Modest but real. This is why CAB is still standard in some countries and centres.

The modern challenge to classical CAB

Since around 2015, several trials have shown that newer androgen receptor inhibitors combined with an LHRH agonist beat classical CAB with bicalutamide:

• ENZAMET (2019) - enzalutamide + LHRH vs bicalutamide + LHRH; better overall survival with enzalutamide
• TITAN (2019) - apalutamide + LHRH; similar survival advantage
• ARCHES (2019) - enzalutamide added to standard ADT; better radiographic PFS
• STAMPEDE abiraterone arm - abiraterone + LHRH; substantial survival benefit

So in high-volume metastatic disease, modern practice often skips bicalutamide altogether and uses enzalutamide, apalutamide, darolutamide, or abiraterone with the LHRH agonist. Bicalutamide remains an option when the newer drugs are unavailable, unaffordable, or not tolerated.

Where Calutide-based CAB still has a role

• Low-volume metastatic disease where trials of newer agents show more modest benefit
• Older or frailer men where the tolerability of bicalutamide beats the newer agents
• Low-resource settings where enzalutamide or apalutamide are unavailable
• Men who cannot tolerate the newer agents due to falls, cognitive change, or cardiovascular limits
• As flare cover only, when the intention is not indefinite CAB

Why monotherapy is different

In classical castration or CAB, testosterone drops to under 50 ng/dL. The man becomes chemically castrated. This produces the full menopause-equivalent picture: hot flushes, loss of libido, erectile dysfunction, muscle mass loss, fatigue, mood changes, bone loss, and (over years) cardiovascular changes.

On bicalutamide 150 mg monotherapy, testosterone stays roughly normal or even rises a bit (feedback from receptor blockade). The man keeps more of his masculine physiology. Libido and sexual function are typically preserved better than with castration. Bone density and muscle mass are less affected. Cardiovascular consequences are milder.

The trade-off - what you accept

To preserve testosterone-driven benefits, you accept:

• High rates of gynecomastia - around 70 percent of men on monotherapy develop breast enlargement, often bilaterally, sometimes with tenderness
• Modestly less anti-cancer effect than combined androgen blockade in aggressive disease
• Occasional hot flushes (but fewer than on castration)
• Small but real liver toxicity risk requiring monitoring

The evidence base

The Early Prostate Cancer Programme (EPC) - three linked trials totalling 8 113 men - directly studied bicalutamide 150 mg in localised and locally advanced disease. Findings:

• Locally advanced disease: bicalutamide reduced disease progression and improved outcomes versus watchful waiting alone
• Localised disease: no clear benefit and possibly worse outcomes; not recommended in localised disease
• Adjuvant after radical prostatectomy: disease progression reduced but with heavy side effect load

On the basis of these findings, bicalutamide 150 mg monotherapy is licensed in Europe and elsewhere for locally advanced disease as an alternative to castration. Not licensed at this dose in the USA. Regulatory differences matter for what your treating team can prescribe.

Not for early localised disease

The EPC data specifically showed that bicalutamide monotherapy in localised, low-risk disease was not helpful and possibly harmful - increased non-cancer mortality without cancer benefit. Regulators withdrew the localised disease indication after these data. Calutide monotherapy is not a treatment for early low-risk prostate cancer - active surveillance, surgery, or radiotherapy fit those settings instead.

The physiology of LHRH agonist flare

LHRH agonists like leuprolide and goserelin work paradoxically. Initially they overstimulate the pituitary's LH-releasing receptors, causing a burst of LH and a spike in testosterone. Testosterone can rise to 150 percent of baseline in the first 1-2 weeks before the pituitary desensitises and testosterone falls.

For most men this transient rise is asymptomatic. For men with bone metastases, especially in the spine, this "flare" can produce:

• Worsening bone pain
• Rare but serious spinal cord compression
• Urinary retention if there is significant prostate obstruction
• Occasional cardiovascular events

How Calutide prevents flare

Bicalutamide blocks the androgen receptor within days of starting. When the LHRH-induced testosterone rise arrives, receptors are already occupied by bicalutamide, and the testosterone cannot signal. Flare symptoms are largely prevented.

The standard flare cover regimen

• Start bicalutamide 50 mg daily 3-7 days before the first LHRH injection
• Continue for 2-4 weeks after the first injection
• Stop bicalutamide once testosterone is confirmed at castrate level, unless combined androgen blockade is intended long-term
• If CAB is intended long-term, just continue bicalutamide indefinitely at 50 mg

Who especially needs flare cover

• Any man with symptomatic bone metastases - especially spinal metastases where cord compression could be catastrophic
• Men with significant urinary obstruction from prostate enlargement
• Men with very high PSA or heavy metastatic burden - more tumour means more tissue that can respond to transient testosterone rise
• Men whose disease is causing pain at baseline

The alternative: LHRH antagonists

LHRH antagonists (degarelix, relugolix) do not cause flare in the first place because they block the pituitary receptor directly rather than overstimulating it. Testosterone drops within days without a preceding rise. Men who need immediate testosterone suppression without any risk of flare are often started on degarelix or oral relugolix rather than an LHRH agonist with bicalutamide flare cover. Both approaches are valid.

How androgens normally work

The testes make testosterone under pituitary control. Testosterone circulates in blood, enters cells, and in prostate tissue converts to the more potent DHT. DHT binds the androgen receptor inside the cell. The bound receptor moves into the nucleus and switches on genes that drive prostate cell growth and function.

In healthy prostate this system builds and maintains normal tissue. In prostate cancer the same system fuels malignant growth. Most prostate cancers depend heavily on androgen receptor signalling, at least initially.

What bicalutamide does

Bicalutamide is a competitive, non-steroidal, first-generation antiandrogen. It enters cells, binds the androgen receptor, and prevents testosterone and DHT from binding. The receptor still moves into the nucleus but cannot switch on its target genes properly. Cancer cell proliferation slows or stops.

Testosterone levels themselves are not lowered by bicalutamide alone. In fact, monotherapy at 150 mg often raises serum testosterone slightly because the pituitary senses reduced androgen signalling and increases LH output. This is why the systemic feminising effects of full castration (loss of muscle, bone, cardiovascular changes) are less pronounced on bicalutamide monotherapy.

The pharmacokinetics

• Half-life around 6 days - long enough for reliable once-daily dosing
• Steady state reached in about 4-6 weeks after starting
• Metabolised in the liver primarily by CYP3A4, then glucuronidated
• Excreted in urine and faeces as inactive metabolites
• Two enantiomers (R and S); the R form is the active one
• Absorption not affected by food

Why side effects centre on breast tissue

When androgen signalling is blocked but testosterone stays available, some of that testosterone gets converted to estradiol by the aromatase enzyme in fat and other tissues. Higher estradiol relative to unopposed androgen effect stimulates breast tissue. Result: gynecomastia and breast tenderness in 50-70 percent of men on 150 mg monotherapy, lower rates on 50 mg CAB. Section 15 covers this.

Bicalutamide advantages

• Once-daily oral dosing
• Widely available and cheap as generic (including Calutide)
• Three decades of safety experience
• Generally well tolerated at 50 mg
• 150 mg monotherapy option preserves libido and physical function
• Fewer CNS side effects than enzalutamide
• Fewer falls, less fatigue than newer drugs in older men

Where newer drugs beat bicalutamide

• High-volume metastatic hormone-sensitive disease (ENZAMET, TITAN, ARCHES)
• Non-metastatic castration-resistant disease (PROSPER, SPARTAN, ARAMIS)
• Aggressive disease where maximum receptor blockade is priority over side effect trade-off
• Post-bicalutamide progression - newer drugs can still work when bicalutamide fails

The trial structure

• Three parallel trials in North America, Scandinavia + rest of Europe, and Australia + Mexico + Israel
• 8 113 men total
• Men with T1-T4, N0/Nx, M0 prostate cancer - localised or locally advanced disease
• Randomised to bicalutamide 150 mg daily or placebo
• Added to standard care - watchful waiting, radical prostatectomy, or radiotherapy
• Long follow-up - primary and secondary publications 2005, 2008, 2010

The main findings by baseline setting

Locally advanced disease (T3-T4 or high-grade):

• Bicalutamide significantly reduced disease progression
• Overall survival benefit in men treated with watchful waiting or radiotherapy
• Established the licensed indication for 150 mg monotherapy in Europe

Localised disease (T1-T2, low-risk):

• No benefit and possibly worse outcomes
• Increased non-cancer mortality
• Led to regulatory withdrawal of localised disease indication

Adjuvant after radical prostatectomy:

• Reduced biochemical progression
• No clear overall survival benefit at long follow-up
• Substantial side effect burden - dropout rates were high

Side effect profile from EPC

• Gynecomastia: 66-75 percent of men on bicalutamide vs 5-8 percent on placebo
• Breast tenderness: 68-73 percent vs 4-8 percent
• Hot flushes: 12-15 percent (much lower than castration)
• Elevated liver enzymes: 3-4 percent
• Discontinuation for side effects: around 20 percent
• Sexual function largely preserved compared with castration

The lasting impact of EPC

The EPC Programme did three important things for clinical practice. It established the licensed 150 mg monotherapy indication in locally advanced disease. It removed the drug from the localised low-risk setting where it did harm. And it quantified the side effect profile at high dose, particularly gynecomastia - which changed practice around prophylactic breast radiotherapy (Section 29). Twenty years on, EPC data still frame how Calutide monotherapy is offered.

The two doses and their uses

Why the doses differ

In CAB, testosterone is already suppressed by the LHRH agonist. Only weak adrenal androgens and residual signalling remain. Bicalutamide 50 mg is enough to cover this. Higher doses do not add benefit and just add side effects.

In monotherapy, testosterone stays at normal or slightly elevated levels. 50 mg is not enough to block that. 150 mg gives the receptor occupancy needed to control disease. This is a real dose-response relationship, not a marketing tier.

Practical dosing rules

• Take one tablet once daily
• Same time each day, with or without food
• Do not split or crush tablets
• If you switch between 50 mg and 150 mg indications, this is a treating team decision - do not adjust yourself
• Duration varies from a few weeks (flare cover) to indefinite (CAB or monotherapy)

Doses that are NOT used

• Twice-daily bicalutamide - long half-life makes this unnecessary
• Higher than 150 mg - no additional benefit, more toxicity
• Lower than 50 mg in an adult man for prostate cancer
• Bicalutamide in premenopausal women or children

Standard baseline tests before starting

• PSA - the tracking marker for treatment response
• Liver function tests (LFTs) - baseline before hepatotoxicity monitoring
• Serum testosterone - especially if CAB, to confirm castrate levels after LHRH takes effect
• Full blood count and kidney function
• Lipid profile and fasting glucose if starting long-term therapy
• Bone density (DXA) if long-term castration-level testosterone is planned
• ECG in men with cardiac history or QT concerns

Common early experiences

• Little or nothing in the first few days
• Some fatigue in the first weeks - often more from the LHRH agonist
• Occasional early breast sensation (fullness, tenderness) - especially at 150 mg
• Hot flushes appearing within 2-4 weeks (mainly LHRH-driven if on CAB)
• PSA usually falls in the first month if the cancer is hormone-sensitive

Signs to call the treating team in the first two weeks

• Yellowing of eyes or skin - possible liver reaction
• Severe abdominal pain or dark urine
• Rash - especially if extensive or with fever
• Sudden shortness of breath, chest pain
• Sudden worsening of bone pain - possible LHRH flare not adequately covered
• Any new leg weakness or bladder/bowel change - urgent, possible spinal cord compression
• Severe fatigue disproportionate to expected

The basic rules

• One tablet once daily
• Same time each day, roughly within a few hours
• With or without food - your choice, be consistent
• Swallow whole with water; do not crush or split
• Morning or evening both work equally well

Anchoring the dose

• With breakfast is common and easy to remember
• Weekly pillbox refilled every Sunday - the single most effective adherence habit
• Phone reminder labelled "Calutide" or "bicalutamide"
• Keep the pack visible - kitchen counter beats bathroom cabinet
• Refill the prescription 2 weeks before you run out
• If travelling, take 30 percent extra supply

Coordinating with LHRH injections

If you are on combined androgen blockade, the LHRH agonist is a monthly or three-monthly injection given at a clinic. Calutide is the daily oral part. The two do not need to be timed together - Calutide is on its own daily rhythm; the injection is on a calendar-based schedule you attend clinic for. Missing a Calutide dose is a small issue (Section 24); missing an LHRH injection matters more and needs a call to the treating team to reschedule.

Long-term adherence is the real challenge

For men on Calutide for years, adherence in year 2 and beyond tends to drift. Side effects fade in urgency, life gets in the way, and it becomes easy to miss doses. The recurrence and progression risk is worse in men who take the drug erratically. If side effects or life pressures are making adherence hard, this is a conversation worth having with the treating team before dose skipping becomes a habit - there are usually better answers than silent dropout.

Food and Calutide absorption

• Take with or without food - your choice
• Grapefruit and grapefruit juice - caution: bicalutamide is metabolised by CYP3A4 which grapefruit inhibits; large amounts can raise drug levels
• Moderate occasional grapefruit is generally fine; daily grapefruit juice is not
• Seville oranges - similar mechanism, treat like grapefruit
• St John's Wort - avoid; enzyme induction lowers bicalutamide levels

Weight and body composition changes

Men on Calutide plus LHRH agonist commonly gain 3-5 kg over the first year as the loss of testosterone shifts body composition:

• Muscle mass declines
• Fat mass rises, especially around the waist
• Insulin sensitivity drops - risk of new type 2 diabetes rises
• Cholesterol drifts up
• Metabolic rate falls slightly

On bicalutamide 150 mg monotherapy (without an LHRH agonist), these changes are much smaller because testosterone stays roughly normal.

A sensible eating pattern on Calutide

• Mediterranean-style - vegetables, whole grains, oily fish, olive oil, moderate lean meat
• Adequate protein - 1.0-1.2 g/kg body weight daily supports muscle
• Cut ultra-processed food - the main source of hidden calories, refined carbohydrate, and salt
• Moderate simple carbohydrates - insulin sensitivity is already impaired
• Adequate calcium and vitamin D for bone protection
• Fibre from vegetables, fruit, whole grains

The exercise-diet combination

Diet alone cannot fully counteract the body composition shift from castration-level testosterone. Resistance training combined with adequate protein is the most effective way to preserve muscle mass and metabolic health. Aim for weight machines or bodyweight exercises 2-3 times a week alongside dietary attention. Section 27 covers exercise in more detail.

The liver angle

Bicalutamide causes elevated liver enzymes in about 3-5 percent of men. Serious drug-induced liver injury is rare but has been reported. Heavy alcohol use amplifies both the risk and the difficulty of interpretation - a raised ALT could be the drug, the drink, or both.

Section 19 covers liver monitoring in detail. On Calutide, LFTs are checked before starting, at 1-3 months, and periodically thereafter.

Sensible position

• Moderate drinking is compatible with Calutide for most men
• Up to 14 units per week spread across the week, per UK CMO guidance
• Alcohol-free days most of the week
• No binge drinking - especially harmful to liver
• Abstain during any active liver enzyme rise
• Cut back during the first months while liver monitoring establishes a stable baseline

Situations to stop or avoid alcohol entirely

• Existing liver disease
• History of alcohol dependence
• Elevated LFTs on routine monitoring
• Concurrent chemotherapy (docetaxel, cabazitaxel)
• Advanced disease with liver metastases
• Multiple hepatotoxic drugs being taken together

Alcohol and hot flushes

Some men on combined androgen blockade find that alcohol triggers or worsens hot flushes and disrupts sleep. This is more marked in men who are chemically castrated (CAB) than on bicalutamide monotherapy where testosterone stays normal. If flushes are troubling on Calutide-based CAB, cutting alcohol back is one of the easier levers.

Common (over 10 percent of men)

• Gynecomastia (breast enlargement) - Section 15; 30 percent on 50 mg, 70 percent on 150 mg
• Breast tenderness - similar rates
• Hot flushes - especially on CAB; Section 16
• Reduced libido on CAB; less on monotherapy; Section 17
• Erectile dysfunction on CAB
• Fatigue - Section 18

Less common (1-10 percent)

• Elevated liver enzymes - Section 19
• Nausea
• Diarrhoea or constipation
• Weight gain - especially on CAB; Section 12
• Mood changes, depression
• Insomnia
• Rash
• Muscle mass loss - on CAB
• Bone density loss - on CAB; Section 20

Uncommon

• Anaemia - especially on CAB
• Fluid retention
• Hair thinning
• Dry skin
• Photosensitivity rash
• QT prolongation - Section 22
• Interstitial lung disease - rare

Rare but serious - stop and seek urgent care

• Drug-induced liver injury - yellowing of eyes/skin, dark urine, right upper abdominal pain
• Severe skin reaction - blistering, peeling, mucosal involvement (Stevens-Johnson syndrome very rare)
• Severe interstitial lung disease - progressive breathlessness, dry cough, fever
• Angina, arrhythmias, or fainting - possible QT-related events
• Anaphylactic reaction - facial swelling, difficulty breathing
• Severe depression with thoughts of self-harm

Comparison note

Calutide has a milder overall side effect profile than the older flutamide (fewer GI issues, less severe liver toxicity) and the newer enzalutamide (less fatigue, less cognitive change, no falls signal). It has more gynecomastia than the newer agents. This is one of the reasons bicalutamide remains widely used - the tolerability profile fits certain men better than the newer options do.

Why it happens

Bicalutamide blocks androgen receptors but does not lower testosterone. Some of that testosterone is converted by aromatase (in fat and breast tissue) into estradiol. In healthy men, testosterone effects on breast tissue balance out estrogen effects. Block the testosterone effect while leaving estrogen unopposed, and breast tissue grows.

What the enlargement looks like

• Usually starts within 2-3 months of starting the drug
• Bilateral in most cases
• Firm glandular tissue under the nipple, not just fat
• Tenderness often precedes visible enlargement
• Can be mildly painful, especially with clothing friction or physical contact
• Progresses over 6-12 months, then usually stabilises
• Partial reversal on stopping the drug, but not always full

Prevention and treatment options

Prophylactic breast irradiation - a single low-dose radiotherapy fraction (12-15 Gy) to each breast before starting Calutide monotherapy reduces gynecomastia rates by roughly half. Well-established option in many European centres. Section 29 covers this.

Tamoxifen 10-20 mg daily - reduces breast tenderness and slows enlargement. Started at the same time as Calutide or when symptoms appear. Evidence supports both prevention and treatment. Small VTE risk to weigh.

Anastrozole 1 mg daily - aromatase inhibitor; blocks estradiol formation. Less effective than tamoxifen for this specific problem in trials.

Surgical management - subcutaneous mastectomy or liposuction for established gynecomastia that has not resolved on stopping the drug.

When to intervene

For men starting Calutide monotherapy at 150 mg, gynecomastia prevention is worth discussing proactively - either prophylactic breast radiotherapy before starting the drug, or tamoxifen from the beginning. Waiting for established gynecomastia and then trying to reverse it is much less effective. For men on 50 mg CAB, prophylactic measures are used less often because rates are lower, though tamoxifen is a reasonable option if breast tenderness becomes bothersome.

A gynecomastia note that matters

Not every breast change on Calutide is drug-related gynecomastia. A hard, unilateral, non-tender lump - especially in an older man with cancer history - needs proper assessment. Male breast cancer is rare but real, and Calutide alone does not explain unilateral masses. Any unusual breast finding should be examined by the treating team.

Rates by regimen

• Calutide + LHRH agonist (CAB): hot flushes in 50-70 percent of men, mainly from the LHRH agonist
• Calutide 150 mg monotherapy: hot flushes in 12-15 percent
• Calutide as flare cover only: hot flushes appear when the LHRH agonist takes effect
• Severity typically peaks in the first 6 months then eases somewhat

What they feel like

• A wave of heat, usually starting in the chest or face
• Sweating - sometimes drenching, sometimes just facial
• Sometimes a racing heart
• Duration typically 1-5 minutes per episode
• Night sweats disrupt sleep - often the more troubling form
• Common triggers: hot drinks, spicy food, alcohol, stress

Non-drug strategies

• Cool bedroom - 17-19 C; fan on if a partner disagrees
• Cotton or bamboo bed linen and nightwear
• Layered clothing during the day - easy to shed
• Avoid triggers - alcohol, spicy meals, hot drinks near bedtime
• Regular exercise - reduces frequency and severity in trials
• Weight management - hot flushes worse at higher BMI
• Paced breathing at flush onset - slow deep breaths can shorten episodes

Drug options for troublesome flushes

• Venlafaxine 37.5-75 mg daily - SNRI with the most trial data in men with androgen-deprivation flushes
• Gabapentin 300-900 mg at bedtime - particularly good for night sweats
• Medroxyprogesterone acetate - progestin; effective but comes with its own side effect load
• Cyproterone acetate - steroidal antiandrogen with progestin action; sometimes used specifically for hot flush relief in CAB
• Clonidine - older option, less effective than SNRIs
• Acupuncture - some evidence in trials of men with androgen-deprivation flushes

Do not use for flushes on Calutide

• Testosterone replacement - contraindicated in prostate cancer therapy
• DHEA supplements - can be aromatised to estrogen; may worsen gynecomastia
• Untested herbal "male hormone balance" formulations

On Calutide monotherapy at 150 mg

• Testosterone stays normal or slightly elevated
• Libido preserved in most men
• Erectile function largely preserved - some reduction but nowhere near castration levels
• Ejaculation and orgasm preserved
• This is one of the main reasons monotherapy is chosen over castration when disease allows

On Calutide plus LHRH agonist (CAB)

• Testosterone at castrate level - under 50 ng/dL
• Libido substantially reduced in most men
• Erectile dysfunction common - 70 percent or more
• Reduced ejaculate volume, sometimes anejaculation
• Effects usually appear within the first months and persist through therapy

Managing sexual side effects

• PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) - can help erectile function, especially on monotherapy where libido remains
• Intracavernosal injections (alprostadil) - work even with severe erectile dysfunction on CAB
• Vacuum erection devices - non-drug option
• Penile implants - for definitive erectile dysfunction when other options fail
• Couples counselling and psychosexual therapy - especially for the libido and intimacy dimensions
• Broadening intimacy beyond penetrative sex - realistic conversation for many CAB clients

Bring this up with the treating team

Sexual side effects are among the most under-reported drug complaints in men - a mixture of embarrassment and assuming there is nothing to be done. Both are wrong. Most urology and oncology teams have systematic pathways to help with sexual function during and after prostate cancer therapy. Some centres have dedicated psychosexual clinics linked to the cancer service. Asking is the door that opens options.

Partner impact

Sexual side effects affect relationships as much as the individual. Involving a partner in early conversations about what to expect, and in decision-making about CAB versus monotherapy where both are options, avoids surprises and preserves the relationship better than silent adaptation.

Where fatigue comes from

• Low testosterone effects on muscle and energy metabolism (CAB, not monotherapy)
• Muscle mass loss reducing baseline metabolic and functional capacity
• Poor sleep from hot flushes and night sweats
• Anaemia - androgen deprivation drops haemoglobin by around 1 g/dL on average
• Reduced physical activity - deconditioning becomes self-reinforcing
• Cancer-related fatigue - especially in metastatic disease
• Mood effects, depression
• Concurrent chemotherapy if applicable

What actually helps

• Regular aerobic and resistance exercise - by far the strongest intervention for cancer-related and androgen-deprivation fatigue in trials
• Adequate protein and calorie intake - counter muscle loss
• Sleep hygiene and treatment of night sweats
• Address anaemia - iron, B12, folate deficiency correction; erythropoietin in specific settings
• Treat depression if present - SNRIs work for mood and can help fatigue
• Vitamin D optimisation - deficiency worsens fatigue
• Cognitive behavioural therapy for cancer-related fatigue - specific programmes exist

The exercise paradox for fatigued men

Fatigue makes exercise feel harder to start. But exercise consistently reduces fatigue better than rest does. This is counter-intuitive but well-supported. Start with what feels sustainable - 10-15 minutes of walking daily is a foundation. Add strength training twice weekly after a few weeks. Group exercise programmes for men on prostate cancer therapy (dedicated survivorship clinics in some centres) can help both structure and social contact.

When fatigue needs urgent assessment

• New or rapidly worsening breathlessness
• Fatigue with chest pain or palpitations
• Fatigue with pallor and rapid onset
• Fatigue with new severe bone pain - possible progression
• Fatigue with severe abdominal pain or jaundice

What the drug does to the liver

• 3-5 percent of men have elevated liver enzymes on bicalutamide
• Usually asymptomatic - picked up on routine bloods
• Serious drug-induced liver injury is rare (well under 1 percent) but has been reported
• Occurs at any dose (50 or 150 mg)
• Most cases appear in the first 3-6 months of therapy
• Reversible on stopping the drug in almost all cases

Standard monitoring schedule

Symptoms that need urgent liver assessment

• Yellowing of eyes or skin (jaundice)
• Dark urine - tea-coloured
• Pale stools - putty-coloured
• Right upper abdominal pain - especially if new
• Persistent nausea or loss of appetite
• Unusual bruising or bleeding
• Itching without rash

Any of these need same-day medical review, LFTs, and consideration of stopping Calutide until liver function is clarified.

Interpreting the numbers

• ALT under 3x upper limit of normal: monitor more frequently but usually continue
• ALT 3-5x upper limit of normal: discuss stopping; investigate other causes
• ALT over 5x upper limit of normal or rising bilirubin: stop Calutide
• Any evidence of clinical hepatitis: stop drug and specialist assessment

After a liver reaction

Most enzyme rises resolve within weeks of stopping bicalutamide. Serious drug-induced liver injury is followed until full recovery. Rechallenge with bicalutamide after a significant hepatic reaction is not usually done - the same drug is likely to produce the same reaction. Enzalutamide or another agent replaces it if hormonal therapy is still needed.

Why CAB damages bone

Testosterone (and estradiol converted from it) supports bone remodelling in men just as estrogen does in women. Dropping testosterone to castrate level accelerates bone resorption. Men on long-term androgen deprivation lose bone density at 2-5 percent per year in the hip and spine, especially in the first years. Fracture risk climbs measurably.

Fracture data

Meta-analyses of men on long-term androgen deprivation show fracture rates approximately double compared with age-matched men not on ADT. Hip fractures particularly matter - one-year mortality after hip fracture in an older man is around 20-25 percent. Bone protection is therefore not cosmetic.

The bone protection plan for men on CAB

Every man starting long-term CAB should have:

• Baseline DXA (bone density) scan
• Vitamin D level checked and corrected if deficient
• Calcium intake reviewed and supplemented to reach 1 000-1 200 mg daily
• Vitamin D3 supplement 800-1 000 IU daily unless replete
• Weight-bearing and resistance exercise regularly
• Repeat DXA every 2 years
• Fall risk assessment especially in older men

When to add a bone-modifying drug

Indications for adding a bisphosphonate or denosumab:

• Baseline T-score below -2.0 on DXA
• T-score falling below -2.0 during therapy
• Any prior fragility fracture
• Rapid bone density loss between DXA scans
• High FRAX risk score
• Bone metastases (different indication and dosing)

Options:

• Denosumab (Prolia 60 mg subcutaneous twice yearly) for bone protection; higher dose (Xgeva) for bone metastases
• Zoledronate 4-5 mg IV once yearly or every 3-4 weeks in metastases setting
• Alendronate or risedronate oral - effective but strict dosing rules

Bicalutamide 150 mg monotherapy - the different story

On monotherapy testosterone stays normal or slightly elevated. Bone density is largely preserved. Some evidence even suggests improved bone density from the higher estradiol resulting from unopposed testosterone conversion. Fracture risk is much closer to baseline than on CAB. Bone monitoring and protective drugs are usually not needed for monotherapy clients unless they have prior osteoporosis. This is one of the significant quality-of-life advantages of monotherapy.

CAB and cardiovascular risk

Long-term androgen deprivation (LHRH agonist plus bicalutamide) has been linked to modestly increased cardiovascular events in observational cohorts:

• Weight gain and increased body fat
• Insulin resistance and higher rate of new-onset type 2 diabetes
• Modest lipid changes - LDL rise, triglyceride rise
• Small increase in coronary events - most seen in men with pre-existing cardiovascular disease
• Effect appears to accumulate over years of therapy

Monotherapy at 150 mg

Cardiovascular impact is much smaller because testosterone stays normal. The metabolic package that drives cardiovascular risk on CAB (weight gain, insulin resistance, lipid changes) is largely absent. Cardiovascular events on 150 mg monotherapy in the EPC trials were similar to placebo, with one exception - a small signal of non-cancer mortality in low-risk localised disease that led to withdrawal of that indication.

Standard cardiovascular protection for men on long-term Calutide

• Baseline BP, lipids, fasting glucose or HbA1c before starting
• BP at each clinic visit
• Lipids and HbA1c yearly during long-term therapy
• Standard cardiovascular prevention - treat hypertension, statin if indicated, treat diabetes
• Encourage smoking cessation - one of the biggest reversible risks
• Weight management and exercise - counters the metabolic drift
• Cardiovascular risk calculator (QRISK, ASCVD, SCORE2) used to guide statin decisions

Cardiovascular events are a bigger issue than the cancer for many men

For men diagnosed with prostate cancer in their 60s and 70s, cardiovascular disease is often the eventual cause of death - not the cancer. This is especially true for men with lower-risk disease on long-term hormonal therapy. Managing cardiovascular risk factors during the years on Calutide matters as much as taking the drug itself. Do not lose sight of general prevention while focused on the cancer plan.

Cardiovascular symptoms to flag urgently

• Chest pain or discomfort, especially on exertion
• Unusual breathlessness
• Ankle swelling that is new
• Fainting or near-fainting on exertion
• Sustained palpitations
• Sudden severe headache with visual changes

What the data show

• Bicalutamide can prolong QT interval, though modestly
• Clinically important arrhythmias are rare
• Risk climbs when combined with other QT-prolonging drugs
• Older men and men with structural heart disease at higher risk
• Electrolyte disturbances (low potassium, low magnesium) amplify the risk

When to be careful

• Baseline ECG recommended in men with prior cardiac history before starting Calutide long-term
• Baseline electrolytes - correct any low potassium or magnesium before starting
• Congenital long QT syndrome - discuss with a cardiologist before starting
• Prior torsades or unexplained cardiac arrest - Calutide relative contraindication
• Bradycardia or heart block

QT-prolonging drugs to watch for

Common medications that add QT effect on top of Calutide:

• Antiarrhythmics - amiodarone, sotalol, dronedarone
• Some antibiotics - macrolides (azithromycin, clarithromycin), fluoroquinolones (moxifloxacin, ciprofloxacin), some antifungals (ketoconazole, fluconazole)
• Antipsychotics - haloperidol, quetiapine, ziprasidone
• Some antidepressants - citalopram at higher doses, tricyclics
• Ondansetron at higher IV doses
• Methadone
• Hydroxychloroquine, chloroquine

This is not exhaustive. Any new prescription in a Calutide client should be checked for QT effect and interaction potential.

Symptoms of dangerous QT prolongation

• Unexplained fainting - especially with exertion
• Palpitations with dizziness
• Fluttery sensations with near-fainting
• Seizure-like episode - can be arrhythmia-induced syncope

Any of these need urgent ECG and cardiology assessment.

Serious - watch closely

• Warfarin and other coumarin anticoagulants - bicalutamide can raise warfarin levels and prolong INR; check INR more frequently after starting or dose change
• Terfenadine, astemizole, cisapride - largely withdrawn but occasionally still encountered; contraindicated with bicalutamide (QT plus metabolism concerns)
• Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) - can raise bicalutamide levels; caution and dose review
• Strong CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, St John's Wort) - lower bicalutamide levels; may reduce efficacy

Moderate - inform prescriber

• Other QT-prolonging drugs - Section 22 details
• Other hepatotoxic drugs - additive liver load
• Grapefruit and Seville orange in large quantities - CYP3A4 inhibition
• Direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) - less well studied but interaction unlikely to be clinically important; watch for bleeding
• Antiretrovirals and antifungals - CYP3A4 pathway shared

Usually safe together

• LHRH agonists (leuprolide, goserelin, triptorelin) - deliberately combined in CAB
• LHRH antagonists (degarelix, relugolix)
• Bone-modifying agents (denosumab, zoledronate)
• Most antihypertensives
• Statins (atorvastatin, rosuvastatin, simvastatin, pravastatin)
• Most SSRIs and SNRIs including venlafaxine and duloxetine for hot flushes
• PDE-5 inhibitors (sildenafil, tadalafil) for erectile dysfunction
• Standard vitamins - D3, calcium, B12
• Paracetamol at usual doses - preferred pain reliever

The everyday reminder

Tell every pharmacist and every doctor that you take Calutide. Over-the-counter "male vitality" or "prostate wellness" supplements are common and some contain saw palmetto, DHEA, tribulus, or other components that may interact or work against the drug's intended effect. Standard multivitamins are fine; anything marketed to men for hormonal effects should be checked with the treating team first.

The rule

• Within 12 hours of usual time: take the missed dose now
• More than 12 hours late: skip it, take the next dose at the usual time
• Never double up to catch up
• A single missed dose has no clinical consequence
• Two or three missed days - just restart at usual dose

The long half-life buffer

Because bicalutamide takes about 6 days to halve in your bloodstream, a single missed dose barely changes drug levels. Steady state persists for many days. This is different from short-half-life drugs where a missed dose leaves you effectively untreated for a day.

Restarting after a longer gap

• Missed a week: restart at usual dose
• Missed 2-4 weeks: restart at usual dose but call the treating team at next opportunity
• Stopped for months: call before restarting - the treating team may want a review and updated PSA and blood tests before restart
• If on CAB, remember the LHRH agonist injection schedule is independent - missing the injection matters more than missing bicalutamide

When missed doses become a pattern

Isolated missed doses are fine. A pattern of missed doses over weeks or months does affect outcomes. If you find yourself missing doses regularly, this usually points to one of:

• Side effects that make the drug feel intolerable - discuss with treating team
• Cost issues - generic versions like Calutide are cheap; discuss prescription options
• Ambivalence about continuing therapy - honest conversation is better than silent dropout
• Life stress that makes daily attention difficult - simplify the reminder system

What changes with age

• Baseline bone density lower - fracture risk climbs faster on CAB
• Muscle mass lower - loss on CAB affects function sooner
• Falls risk higher - fractures more likely to be consequential
• Cardiovascular comorbidity common - metabolic side effects of CAB more likely to matter
• Polypharmacy interactions rise
• Cognitive reserve lower - fatigue and mood effects add to age-related change
• Life expectancy calculation affects whether long-term therapy makes sense

Frailty over age

Age alone is a poor guide to what men can tolerate. A fit, active 78-year-old with newly diagnosed metastatic disease may do very well on CAB. A frail 68-year-old with multiple comorbidities may suffer disproportionately. Geriatric assessment tools (G8, CGA) are used in many centres to guide these decisions rather than birthdate alone.

Practical adjustments for older men

• Same 50 or 150 mg dose - no age-based reduction
• Earlier bone protection - lower threshold to add bisphosphonate or denosumab if on CAB
• Attention to falls - physiotherapy for balance training when energy drops
• Simplify medication regimens where possible
• Regular medication reviews - deprescribe unnecessary drugs to reduce interactions
• Watch for cognitive change - do not attribute all fog to age; consider depression, sleep disturbance, medication side effects
• Consider monotherapy at 150 mg where disease allows - avoids many CAB-related problems in older men

Choosing Calutide over newer agents in older men

Enzalutamide has been associated with increased falls, seizures, and cognitive changes in some older men. Apalutamide has similar concerns. Bicalutamide often tolerates better in this population despite modestly less anti-cancer effect. Where the newer drugs are affordable and available, the choice between bicalutamide-based CAB and a newer agent in an older man often comes down to a tolerability judgment - the treating team weighs individual factors.

Common sick days

• Cold, flu, mild viral illness: continue Calutide if you can keep tablets down
• Stomach bug with vomiting: if you cannot keep tablets down for more than 24 hours, temporary hold is reasonable; the long half-life means brief interruption has minimal effect
• Fever without fluid loss: continue normally
• COVID-19 or similar: continue Calutide; the drug does not affect infection outcome

Hospital admissions

• Tell the admitting team you are on Calutide - it can otherwise be missed on a busy admission
• The drug is usually continued through hospital stays
• If unable to swallow, bicalutamide can be paused for a few days without significant effect
• Any new antibiotic or antifungal starting in hospital - check for QT and CYP3A4 interactions (Section 22, 23)
• Immobilisation from admission - matters if you already have low bone density; discuss

Concurrent chemotherapy

In advanced disease, chemotherapy (docetaxel or cabazitaxel) may be added to hormonal therapy. Bicalutamide is typically continued alongside chemotherapy, though the treating team may adjust based on liver function and other tolerability. This is a specialist decision.

When to hold Calutide temporarily

• Acute drug-induced liver injury (jaundice, dark urine, LFT rises significantly)
• Severe skin reaction
• Severe interstitial lung symptoms (rare but reported)
• Severe QT-related symptoms with cardiac assessment pending
• Severe fluid loss preventing oral intake for over 24-48 hours
• Under treating team guidance around major surgery or critical illness

The evidence in prostate cancer

• Meta-analyses show reduced prostate cancer mortality in men who exercise regularly after diagnosis
• Randomised trials confirm reductions in ADT-related fatigue, improved quality of life
• Exercise preserves muscle mass and bone density on CAB
• Reduces cardiovascular event risk in the long term
• Improves mood, cognitive function, and sleep
• Reduces the muscle-to-fat ratio drift that CAB drives

What to aim for

ACS and ASCO exercise guidelines for cancer survivors recommend:

• 150 minutes per week of moderate aerobic exercise - walking, swimming, cycling
• OR 75 minutes per week vigorous aerobic
• Plus resistance training 2-3 times weekly - critical for muscle mass on CAB
• Flexibility and balance work - especially for older men with fall risk
• Any activity is better than none; scale up gradually

Resistance training specifics

For men on CAB, resistance training matters more than for the general population because of muscle loss risk:

• Compound movements - squats, deadlifts, presses, rows
• Weights heavy enough that the last few reps are hard
• Progressive - increase gradually over weeks and months
• Adequate protein intake (1.0-1.2 g/kg body weight daily)
• Not overtraining - fatigue on CAB means recovery matters more
• Supervised training initially if new to weights

Bone metastases and exercise

Men with bone metastases can and should exercise, but with modification. Physiotherapy-guided programmes reduce fracture risk and preserve function even in advanced disease. High-impact activities and heavy loading of affected bones are usually avoided; walking, cycling, swimming, and modified resistance training remain valuable. Discuss with the treating team - a physiotherapist familiar with cancer bone disease can build a safe programme.

Stop exercise and get review if

• New chest pain or unusual shortness of breath
• Fainting or near-fainting
• Palpitations or irregular rhythm
• Sudden severe bone pain during activity - possible fracture
• New localised weakness (leg dragging, sensory change) - urgent, possible spinal cord compression

The LHRH agonist options

• Leuprolide (Lupron, Prostap) - monthly or 3-monthly injection; most widely used
• Goserelin (Zoladex) - monthly or 3-monthly subcutaneous implant
• Triptorelin (Decapeptyl) - monthly, 3-monthly, or 6-monthly injection
• Histrelin (Vantas) - yearly implant

How the combination works together

• LHRH agonist drops testosterone to castrate level over 3-4 weeks
• Bicalutamide blocks any residual androgen signalling from adrenal androgens or intracellular DHT
• Bicalutamide also covers the transient testosterone rise (flare) from LHRH agonist start
• Combined effect is close to complete androgen blockade
• Meta-analysis shows modest survival benefit versus LHRH alone

Practical rhythm of CAB

Once established, the therapy has two components on different clocks:

• Daily Calutide tablet - one every day, at the same rough time
• Monthly or three-monthly clinic visit for the LHRH injection - book ahead, do not miss
• Regular blood tests - PSA every 3-6 months, testosterone occasionally to confirm castrate levels, LFTs per Calutide monitoring, calcium and phosphate if on bone-modifying agents
• Bone density (DXA) every 1-2 years
• Yearly cardiovascular review

LHRH antagonist alternative

LHRH antagonists (degarelix injection, relugolix oral tablet) do not cause a flare because they block the pituitary receptor directly. Some men are treated with an LHRH antagonist plus bicalutamide, or with an LHRH antagonist alone. Relugolix is particularly interesting because it is oral - no injection needed - and has shown less cardiovascular event signal in the HERO trial. Where these newer options are available and affordable, some men prefer them.

When to consider stopping bicalutamide within CAB

Sometimes after the initial flare cover and stabilisation, the bicalutamide component of CAB can be stopped while the LHRH agonist continues. This is called "monotherapy with LHRH" and it works nearly as well as full CAB with fewer side effects. The decision depends on disease characteristics and treating team preference. Do not stop bicalutamide without discussion - the decision is not automatic.

What it involves

• Single fraction of external beam radiotherapy, typically 12-15 Gy
• Given to each breast in an outpatient session lasting 15-30 minutes
• Done before starting Calutide or within the first 2-4 weeks - earlier is more effective
• Localised to breast tissue with minimal deep dose
• No hospital admission required

The evidence

• Randomised trials show 50-60 percent reduction in gynecomastia rates
• Reduction in breast tenderness slightly less pronounced
• Better outcomes when done before starting bicalutamide
• Less effective when delayed until gynecomastia has developed

Side effects of the radiotherapy

• Mild skin redness at the treatment site
• Transient breast discomfort
• Very small theoretical long-term risk of radiation-induced breast cancer - real but tiny at these doses
• Slight change in skin pigmentation possible

Who should consider this

Men starting bicalutamide 150 mg monotherapy should have this option offered. Some centres offer it routinely; others discuss it only when the man raises breast concerns. Ask about it if you have not been offered - especially if body image or clothing considerations are important to you. Prophylactic tamoxifen 10-20 mg daily is an alternative or additional option (Section 15).

Not indicated for men on CAB at 50 mg

Gynecomastia rates on 50 mg CAB are much lower (30 percent versus 70 percent on monotherapy) and the balance of benefit versus radiotherapy risk is less clearly favourable. Prophylactic tamoxifen is more commonly used in this setting if breast issues emerge.

Typical durations by indication

When Calutide stops working

Bicalutamide-resistant progression is signalled by:

• Rising PSA on therapy
• New symptomatic disease (bone pain, urinary symptoms)
• New metastases on imaging
• Progressive lymphadenopathy on scans

At this point the disease has become castration-resistant prostate cancer (CRPC) if testosterone is confirmed at castrate levels. Treatment moves to second-line therapies - see Section 31.

The antiandrogen withdrawal response

In roughly 20 percent of men, stopping bicalutamide when PSA is rising produces a paradoxical PSA fall for weeks to months. This "antiandrogen withdrawal response" reflects mutations that make the receptor read bicalutamide as an activator rather than a blocker. Historically this was tried before switching to second-line therapy. Modern practice often skips this and moves directly to enzalutamide, abiraterone, or another next-line drug based on trial evidence.

Stopping mechanics

Calutide does not need tapering. Stopping is a simple cessation. Blood levels drop over 2-3 weeks. Testosterone signalling recovers over the same period. Side effects fade over weeks to a few months - gynecomastia often only partly reverses, especially if it was well established. There is no rebound cancer effect from stopping in the sense that the tumour does not accelerate faster than it was going to anyway.

Second-generation androgen receptor inhibitors

mHSPC = metastatic hormone-sensitive; nmCRPC = non-metastatic castration-resistant; mCRPC = metastatic castration-resistant.

When to switch from Calutide to a newer agent

• Progression on bicalutamide-based CAB - PSA rising on castrate testosterone
• New metastases on imaging
• Symptomatic progression
• High-risk newly diagnosed metastatic disease where newer agents give better first-line outcomes (ENZAMET, TITAN, ARCHES, LATITUDE, STAMPEDE)
• Non-metastatic castration-resistant disease where enzalutamide, apalutamide, and darolutamide have direct trial evidence

Trade-offs of newer agents

Advantages:

• Better anti-cancer effect in most settings
• Less gynecomastia
• Effective when bicalutamide has failed

Trade-offs:

• More expensive - often meaningful for out-of-pocket costs
• Enzalutamide and apalutamide - falls, seizure risk, cognitive change (less with darolutamide)
• Abiraterone - needs concurrent low-dose prednisone; blood pressure, potassium, LFT monitoring
• Different rash profiles (apalutamide has more)
• Availability varies by country and insurance

The switching conversation

Deciding whether to start with bicalutamide-based CAB and switch later, or start with a newer agent upfront, is a common question. In high-volume metastatic hormone-sensitive disease the evidence increasingly favours upfront enzalutamide, apalutamide, or abiraterone over classical CAB. In low-volume or asymptomatic disease, or in older frailer men, bicalutamide-based CAB remains a reasonable option. This is a treating team decision informed by individual factors.

Absolute contraindications

• Known hypersensitivity to bicalutamide or excipients
• Women and children - not indicated
• Pregnancy - teratogenic; not applicable to men but relevant if bicalutamide is being considered off-label
• Severe hepatic impairment at baseline
• Prior drug-induced hepatitis from bicalutamide - no rechallenge
• Concurrent terfenadine, astemizole, or cisapride (rarely encountered but firm interaction)

Relative contraindications - use with care

• Moderate hepatic impairment
• Congenital long QT syndrome or family history of sudden cardiac death
• Concurrent strong QT-prolonging drugs where combination cannot be avoided
• Bradycardia or heart block
• Severe uncontrolled cardiovascular disease
• Localised low-risk prostate cancer at monotherapy dose (harmful per EPC data)
• Warfarin therapy without frequent INR monitoring

Reasons to stop Calutide

• Drug-induced liver injury of any severity
• Severe skin reaction
• Interstitial lung disease
• Symptomatic QT prolongation
• Disease progression despite therapy - switch to next-line agent
• Intolerable side effects despite management
• Completion of planned course (e.g. flare cover)
• Change to newer androgen receptor inhibitor as part of trial evidence-based upgrade

Stopping mechanics

Calutide does not need tapering. The long half-life means the drug clears over 2-3 weeks after the last dose. Testosterone signalling recovers over the same period. Side effects fade over weeks to a few months. There is no rebound cancer risk from stopping - the concern is losing ongoing anti-cancer effect, not any drug withdrawal danger. Where continued androgen blockade is needed, the switch to another agent is planned before stopping bicalutamide rather than stopping first.

Storage

• Room temperature under 25 C, in original packaging
• Not in the bathroom - humidity degrades tablets
• Not in a hot car
• Out of reach of children and pets - bicalutamide in a small child would be dangerous
• Do not use past expiry date
• Return unused tablets to a pharmacy - do not flush or bin

Travel

• Pack Calutide in hand luggage, not checked baggage
• Take 30 percent more than you strictly need for the trip
• Original packaging with pharmacy label for customs
• Bring a letter from the treating team if travelling with a long supply
• Time zone changes - shift the dose gradually over a few days if the change is over 4 hours
• Coordinate LHRH injection schedule with travel - do not miss injections
• Travel insurance - declare prostate cancer and current therapy

Surgery on Calutide

• Tell every surgeon and anaesthetist about Calutide
• Major surgery - Calutide usually continued, though the treating team may pause briefly around big procedures
• Minor surgery and dental work - continue normally
• If you take warfarin, INR management around surgery needs careful coordination given the bicalutamide interaction
• Anaesthetists should know about QT concerns if you have any cardiac history

Yearly review checklist

A yearly Calutide review typically covers:

• PSA trend - the main disease marker
• Symptom review - hot flushes, gynecomastia, sexual function, fatigue, mood
• Adherence check - honest conversation about missed doses
• Full LFTs
• Full blood count
• Kidney function, calcium, phosphate
• Lipids, HbA1c or fasting glucose
• BP and cardiovascular risk assessment
• Bone density (DXA) every 1-2 years if on CAB
• Testosterone if uncertain about castrate status
• Imaging as clinically indicated
• Any new medications and interaction check
• Whether to continue, switch, or extend therapy
• Life issues - work, exercise, mental health, relationships

A closing thought

Calutide is an old, well-understood drug used across many clinical settings in prostate cancer. It is one of several options in a landscape that has expanded with enzalutamide, apalutamide, darolutamide, abiraterone, and other targeted agents. For many men - especially those where cost, tolerability, or specific clinical context matter - bicalutamide remains a solid, familiar, and effective choice. Approaching it as a partnership over years rather than a passive prescription, taking side effects seriously enough to raise them with the treating team, and staying active and engaged with general health, are the elements that make long-term therapy work.